前列腺癌患者直肠系膜淋巴结转移的相关因素
回顾性病例对照研究纳入135例前列腺癌患者,采用PSMA PET/CT评估直肠系膜淋巴结转移,45例阳性者按年龄和ISUP分级1:2匹配对照。多因素分析显示,非直肠系膜淋巴结转移(OR 32.86)和前列腺体积较大(OR 2.00)与直肠系膜淋巴结受累独立相关。作者建议对存在非直肠系膜区域淋巴结转移或前列腺体积较大的患者仔细评估直肠系膜区。
要点
- 非直肠系膜淋巴结转移与直肠系膜淋巴结受累独立相关(OR 32.86)。
- 前列腺体积较大与直肠系膜淋巴结受累独立相关(OR 2.00)。
- 单因素中PSA较高和精囊侵犯更常见,但多因素模型未达显著。
核心结论
- 非直肠系膜淋巴结转移和前列腺体积增大与前列腺癌直肠系膜淋巴结受累独立相关,作者认为对存在非直肠系膜区域淋巴结转移或前列腺体积较大的患者应仔细评估直肠系膜区,可能影响治疗计划和放疗野设计。
研究设计与样本
- 回顾性病例对照研究,纳入135例前列腺癌患者,其中45例直肠系膜淋巴结摄取阳性者按年龄和ISUP分级1:2匹配对照,所有患者均有mpMRI和活检结果,采用PSMA PET/CT检测直肠系膜淋巴结转移。
关键影像表现/征象
- 直肠系膜淋巴结摄取阳性者单因素分析PSA较高(19.60 vs. 8.23 ng/mL,p=0.02)。
- 直肠系膜淋巴结摄取阳性者精囊侵犯更常见(44.4% vs. 26.7%,p=0.04)。
诊断标准与关键数值
- 多因素分析中非直肠系膜淋巴结转移与直肠系膜淋巴结受累相关(OR 32.86,CI 7.10-152.03,p<0.001)。
- 多因素分析中前列腺体积较大与直肠系膜淋巴结受累相关(OR 2.00,CI 1.14-3.51,p=0.016)。
- 单因素分析中PSA较高(19.60 vs. 8.23 ng/mL,p=0.02)和精囊侵犯更常见(44.4% vs. 26.7%,p=0.04)与直肠系膜淋巴结摄取阳性相关,但多因素模型未达显著。
临床应用与阅片要点
- 作者认为,对存在非直肠系膜区域淋巴结转移或前列腺体积较大的患者,应仔细评估直肠系膜区,可能影响治疗计划和放疗野设计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate radiological and pathological factors associated with mesorectal lymph node (MLN) metastases in prostate cancer patients, as detected by Prostate Specific Membrane Antigen (PSMA) imaging with Positron Emission Tomography/Computed Tomography (PET/CT).
METHODS: In a retrospective case-control study of 135 prostate cancer patients who underwent PSMA PET/CT between January 2022 and October 2024, forty-five patients with positive mesorectal nodal uptake were matched 1:2 with control patients based on age and International Society of Urological Pathology (ISUP) grade. All patients had multiparametric prostate MR imaging and biopsy results available. We analyzed radiological features (PI-RADS scores, extraprostatic extension, seminal vesicle invasion) and histopathological characteristics (ISUP grade, percentage of positive biopsy cores, cribriform growth, perineural invasion) using univariable and multivariable logistic regression.
RESULTS: In multivariable analysis, two independent factors associated with mesorectal lymph node involvement were identified: presence of non-mesorectal lymph node metastases (OR 32.86, CI: 7.10-152.03, p < 0.001) and larger prostate volume (OR 2.00, CI: 1.14-3.51, p = 0.016). Patients with positive MLN uptake had higher prostate specific antigen (PSA) levels (19.60 vs. 8.23 ng/mL, p = 0.02) and more frequent seminal vesicle invasion (44.4% vs. 26.7%, p = 0.04) in univariable analysis, but these associations were not significant in the multivariable model.
CONCLUSION: Non-mesorectal lymph node metastases and increased prostate volume are independently associated with mesorectal lymph node involvement in prostate cancer. These findings suggest that careful evaluation of the mesorectal region should be performed in patients with non-mesorectal regional lymph node metastases or larger prostate volumes, potentially impacting treatment planning and radiation field design.
引用
- Pohl M, Elshikh A, Mercaldo S, et al. Factors associated with mesorectal lymph node metastasis in prostate cancer patients. Abdom Radiol (NY). 2025. PMID: 40576667. doi:10.1007/s00261-025-05086-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。